Raymond Alexanian
- Hematology top 0.02%
- Molecular Biology top 0.5%
- Oncology top 0.2%
- Genetics top 0.1%
- Pathology and Forensic Medicine top 0.5%
- Co-authors
- Meletios Α. DimopoulosBart BarlogieKay DelasalleDonna WeberB BarlogieLon SmithLia A. MoulopoulosJoshua Epstein
- Topics
- Multiple Myeloma Research and Treatments (171 papers)Cancer Treatment and Pharmacology (63 papers)Protein Degradation and Inhibitors (56 papers)
- Cited by
- HematologyGeneticsOncology
- Partner nations
- United StatesGreeceUnited Kingdom
In The Last Decade
Raymond Alexanian
224 papers receiving 13.5k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Hematology 10.5k
- Molecular Biology 7.1k
- Oncology 6.0k
- Genetics 3.2k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by Raymond Alexanian
This map shows the geographic impact of Raymond Alexanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Alexanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Alexanian more than expected).
Fields of papers citing papers by Raymond Alexanian
This network shows the impact of papers produced by Raymond Alexanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Alexanian. The network helps show where Raymond Alexanian may publish in the future.
Co-authorship network of co-authors of Raymond Alexanian
This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Alexanian. A scholar is included among the top collaborators of Raymond Alexanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Alexanian. Raymond Alexanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 75 | |
| 2 | 39 | |
| 3 | 18 | |
| 4 | 6 | |
| 5 | 80 | |
| 6 | 23 | |
| 7 | 76 | |
| 8 | 20 | |
| 9 | 40 | |
| 10 | 110 | |
| 11 | 34 | |
| 12 | 82 | |
| 13 | Long-term follow-up after high-dose therapy for high-risk multiple myeloma | 1 |
| 14 | 117 | |
| 15 | 28 | |
| 16 | 5 | |
| 17 | 6 | |
| 18 | 301 | |
| 19 | 17 | |
| 20 | 13 |
About Raymond Alexanian
Raymond Alexanian is a scholar working on Hematology, Genetics and Oncology, having authored 226 papers that have together received 14.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (171 papers), Cancer Treatment and Pharmacology (63 papers) and Protein Degradation and Inhibitors (56 papers). The work is most often cited by research in Hematology (10.5k citations), Genetics (3.2k citations) and Oncology (6.0k citations). Raymond Alexanian has collaborated with scholars based in United States, Greece and United Kingdom. Frequent co-authors include Meletios Α. Dimopoulos, Bart Barlogie, Kay Delasalle, Donna Weber, B Barlogie, Lon Smith, Lia A. Moulopoulos, Joshua Epstein, Barthel Barlogie and P Selvanayagam. Their work appears in journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.